Filters

Anti-HIV-2 gp32, Horseradish Peroxidase Labled (Recombinant)

Anti-HIV-2 gp32, Horseradish Peroxidase Labled (Recombinant) size: 0.5 mg 1297

Supplier ABBEX
Price 1297
Size 0.5 mg
CategoryProteins And Peptides
Target Horseradish Peroxidase Labled, 2 gp32
ImmunogenSee techfile
Reactivity Mouse, Rat, Human
FormUnconjugated
PurificationAffinity purified
ApplicationsWB (for other see techfile or inquire)
Stock availabilityShipped within 5-10 working days
Storage conditions Avoid repeated freeze/thaw cycles, Aliquot and store at -20 °, C
WarningsThis product is for research use only
Gene AIDS is a condition in humans in which progressive failure of the , HIV is present as both free virus particles and virus within infected , Within these bodily fluids, Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 , depending on the HIV subtype, gp120 are used for production of diagnostic detection antibodies, or , p17, p55 immunodominant epitopes and envelope glycoproteins, recombinant HIV 1 and 2 gag gene proteins p24, semen,  ,  ,  , (HIV) is a , (a subgroup of , HIV infection , Infection with HIV occurs by the transfer of , The , acquired immunodeficiency syndrome(AIDS), allows life-threatening , and over time , and , blood, breast milk, cancers , human immunodeficiency virus , immune cells, immune system , lentivirus , opportunistic infections , pre-ejaculate, retrovirus) that causes , to thrive, vaginal fluid, years
Source proteins, Recombinants or rec
Grouprecombinants
Gene target Horseradish Labled, HIV-2 gp32
Short name Horseradish Peroxidase Labled (Recombinant), Anti-HIV-2 gp32
Technique E, abbex advises they will be reconstituted in a buffer soluion or culture medium for cell culture, coli recombinant proteins are , supplied as white sterile powder lyopillized, Recombinant, genetic recombinations , in Escherichia coli
Alternative name Horseradish Peroxidase Labled (recombinant), antibody to-human immunodeficiency virus-2 gp32
Alternative techniquerec

Subscribe to our Newsletter